We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Devgen Appoints a New Independent Director of the Board
News

Devgen Appoints a New Independent Director of the Board

Devgen Appoints a New Independent Director of the Board
News

Devgen Appoints a New Independent Director of the Board

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Devgen Appoints a New Independent Director of the Board"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Devgen nv (EVG) has announced that Mrs. Ruth Devenyns has been appointed independent director of the Board for a term of two years.

Mrs. Devenyns has a long standing experience in the biotechnology sector.

A former analyst and investment banker, Ruth Devenyns was in charge of the venture capital activities in the sector at KBC Private Equity until end of March 2012.

She was involved in several IPO’s, private placements and M&A-transactions and held various directorships including Ablynx, Applied Maths and Biocartis.

At KBC Private Equity she also managed various investments in agro-biotech and seed companies such as CropDesign and Ceres.

Currently, Ruth Devenyns is an independent director at MDx Health and director of FlandersBio, the biotech sector organization in Flanders. This month she will join Korys, the investment structure of the Colruyt family.

Remi Vermeiren, Chairman of Devgen’s Board, welcomed her: "Ruth Devenyns is a valuable addition to the Board. With her eminent expertise in finance and her track record in biotech companies, she will contribute significantly to Devgen’s Board."

Advertisement